GNLX - Genelux Corporation - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

616M

Cash

27.14M

Avg Qtr Burn

-3.499M

Short % of Float

1.13%

Insider Ownership

25.37%

Institutional Own.

1.28%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Olvi-Vec (Olvimulogene nanivacirepvec) + platinum-doublet + bevacizumab Details Ovarian cancer, Cancer, Platinum-resistant ovarian cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Olvi-Vec (Olvimulogene nanivacirepvec) Details Cancer, Small cell lung cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.